Explore 3 Stock Ideas & Industry Insights Download Free Report
Spire Healthcare Group plc (LSE:SPI) published the scheme document on 29 September 2026. It covers the acquisition by Tulip UK Bidco Limited, which acts for funds managed or advised by Toscafund Asset Management LLP, THCP Advisory Limited and Ares Management Limited. The deal is …
•The company remains focused on proteomics services, protein biomarkers, mass spectrometry and chemoproteomics.
•H1 2026Revenuewas £24.0 million, with Clinical revenue up 3% to £20.6 million.
Vulcan Two Group plc (LSE:VUL) released interim results for the six months to 30 June 2026 alongside confirmation of a change of name. The company will become Molecule Group plc, trading under the ticker MOL, with the change expected "in the coming days". A …
ProBiotix Health plc (LSE:PBX) operates in the health and nutrition technology space, with a focus on microbiome-based products and ingredients. Its commercial proposition depends on translating scientific research into consumer and partner products. That makes licensing, distribution, customer adoption andRecurring Revenueimportant drivers of market …
Genus gained 2.53% on 29 September after recent full-year results and continued progress in animal genetics and gene-editing technologies kept the company in focus. TheBusinessis positioned at the intersection of livestock productivity, food security and biotechnology.
Incanthera plc (LSE:INC) made two announcements on 29 September 2026. The first was its final results for the year to 31 March 2026. The second confirmed completion of a £355,000 financing through convertible loan notes (CLNs).
Genflow Biosciences Plc (LSE:GENF), which develops SIRT6 gene therapies for age-related diseases, published unaudited half-year results for the six months to 30 June 2026. All of its human health programmes also moved onto a messenger RNA-lipid nanoparticle (mRNA-LNP) delivery platform.
•H1 2026Revenuereached a record US$1.4 million, up 67% year on year.
In an announcement on 29 September 2026, AstraZeneca set out two linked agreements with Summit Therapeutics Inc. The first is a $2bn strategicInvestmentin newly issued Summit stock. The second is a clinical collaboration to test Sone-Ve with ivonescimab in gastrointestinal cancers.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…